Latest News
Vision for Sarcoma Research & Clinical Trials - Hope for Sarcoma Patients
New Clinical Trials, 2026
*RECRUITING*STRATEGIST-3: 2nd line GIST - imatinib vs IDRX-42, with crossover. Funding available for patient travel. SARC-005: Angiogenic sarcomas (EHE, intimal, and H&N angiosarcoma) - oral immunotherapy. No funding available for patient travel. CHONQUER: 1st line conventional chondrosarcoma - placebo vs. ivosidenib. Funding available for patient travel. POLARIS: 2nd/3rd line leiomyosarcoma - gem/tax + ADIPEG20 vs. gem/tax + placebo. Weekly visits required. No funding available for patient travel.
*COMING SOON*
DCC3009: phase ½ study of pan-KIT inhibitor in patients with GIST.
STRATEGIST-1: 1st line GIST - IDRX-42 vs. imatinib.
EMBOLD: Osteosarcoma, liposarcoma, leiomyosarcoma, and other STS subtypes - anti-B7H3 i.v. drug.
Journal of Surgical Oncology, April 2026
Impact of Surgical Margins in Chest Wall Chondrosarcomas
Chest wall chondrosarcoma is the most common primary malignant bone tumor of the thoracic cage. Owing to
its resistance to chemotherapy and radiotherapy, complete surgical excision with negative margins remains the cornerstone of
treatment. However, the optimal margin width for local control and survival remains uncertain. Short poster description goes here.
Download PDF
Cancer, Jan 2026
Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1
This study suggests that patients with NF1‐associated MPNSTs experience worse outcomes.
Download PDF
Cancer Medicine, Jan 2026
A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas
Complete resection is critical in CIC-rearranged sarcomas (CRS). Chemotherapy benefit remains uncertain, underscoring the need for improved local control and novel, biology-driven therapies.
Download PDF
European Journal of Cancer, Nov 2025
Incidence, prevalence and treatment of patients with Epithelioid Haemangioendothelioma (EHE) in Canada
This is the largest series of EHE patients describing sequential systemic therapies. The role of systemic
therapy in EHE in improving survival remains unclear and prospective studies with comparative arms are needed
to add further insight into this chronic disease
Download PDF